Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 24-Nov-21 4:09 PM View:  | Shreedhar Vijay Chief Commercial Officer | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 186,786 | -- | -- | (100%) 186.79K to 0 | |
| 24-Nov-21 4:08 PM View: | Demski Martha J Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 16,000 | -- | -- | (76%) 21.0K to 5.0K | |
| 24-Nov-21 4:10 PM View: | McFarlane Neil F. Chief Executive Officer Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Grant | 75,000 | -- | -- | 14% 525.0K to 600.0K | |
| 24-Nov-21 4:11 PM View: | Mahoney David L Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 5,000 | -- | -- | (4%) 117.78K to 112.78K | |
| 24-Nov-21 4:09 PM View: | Ericson William W. Director 10% Owner | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 10,000 | -- | -- | (< 1%) 4.63M to 4.62M | |
| 24-Nov-21 4:10 PM View: | Prentiss Christopher B Chief Financial Officer | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Grant | 18,750 | -- | -- | 13% 145.02K to 163.77K | |
| 24-Nov-21 4:10 PM View: | Prentiss Christopher B Chief Financial Officer | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 163,767 | -- | -- | (100%) 163.77K to 0 | |
| 24-Nov-21 4:08 PM View: | Demski Martha J Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 5,000 | -- | -- | (100%) 5.0K to 0 | |
| 24-Nov-21 4:08 PM View: | Richo Anna Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 25,000 | -- | -- | (100%) 25.0K to 0 | |
| 24-Nov-21 4:07 PM View: | MacPhee John A Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 202,000 | -- | -- | (100%) 202.0K to 0 | |
| 24-Nov-21 4:10 PM View: | McFarlane Neil F. Chief Executive Officer Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 600,000 | -- | -- | (100%) 600.0K to 0 | |
| 24-Nov-21 4:09 PM View: | Shreedhar Vijay Chief Commercial Officer | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Grant | 18,750 | -- | -- | 11% 168.04K to 186.79K | |
| 24-Nov-21 4:11 PM View: | Mahoney David L Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 112,781 | -- | -- | (100%) 112.78K to 0 | |
| 24-Nov-21 4:09 PM View: | Ericson William W. Director 10% Owner | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 4,619,800 | -- | -- | (100%) 4.62M to 0 | |
| 24-Nov-21 4:11 PM View: | Bigham Michael Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 10,000 | -- | -- | (100%) 10.0K to 0 | |
| 24-Nov-21 4:09 PM View: | Papapetropoulos Spyridon Director | Adamas Pharmaceuticals Inc (ADMS) | 24-Nov-21 | Disposition (change in control) | 20,975 | -- | -- | (100%) 20.98K to 0 | |
| 23-Jun-21 4:09 PM View: | Shreedhar Vijay Chief Commercial Officer | Adamas Pharmaceuticals Inc (ADMS) | 21-Jun-21 | Market Sale | 6,200 | $5.16 | $31,982.70 | (4%) 171.94K to 165.74K | (58%) |
| 08-Jun-21 5:32 PM View: | Demski Martha J Director | Adamas Pharmaceuticals Inc (ADMS) | 07-Jun-21 | Market Sale (Planned) | 2,000 | $5.17 | $10,340.00 | (9%) 23.0K to 21.0K | (58%) |
| 04-Jun-21 4:17 PM View: | Richo Anna Director | Adamas Pharmaceuticals Inc (ADMS) | 02-Jun-21 | Grant | 5,000 | -- | -- | 25% 20.0K to 25.0K | |
| 04-Jun-21 4:14 PM View: | Ericson William W. Director 10% Owner | Adamas Pharmaceuticals Inc (ADMS) | 02-Jun-21 | Grant | 5,000 | -- | -- | < 1% 4.62M to 4.63M | |
| 04-Jun-21 4:16 PM View: | Papapetropoulos Spyridon Director | Adamas Pharmaceuticals Inc (ADMS) | 02-Jun-21 | Grant | 5,000 | -- | -- | 31% 15.97K to 20.98K | |
| 04-Jun-21 4:13 PM View: | Dier Mardi Director | Adamas Pharmaceuticals Inc (ADMS) | 02-Jun-21 | Grant | 5,000 | -- | -- | 100% 5.0K to 10.0K | |
| 04-Jun-21 4:13 PM View: | Demski Martha J Director | Adamas Pharmaceuticals Inc (ADMS) | 02-Jun-21 | Grant | 5,000 | -- | -- | 28% 18.0K to 23.0K | |
| 04-Jun-21 4:12 PM View: | Bigham Michael Director | Adamas Pharmaceuticals Inc (ADMS) | 02-Jun-21 | Grant | 5,000 | -- | -- | 100% 5.0K to 10.0K | |
| 04-Jun-21 4:15 PM View: | Mahoney David L Director | Adamas Pharmaceuticals Inc (ADMS) | 02-Jun-21 | Grant | 5,000 | -- | -- | 4% 112.78K to 117.78K | |
| 04-Jun-21 4:15 PM View: | MacPhee John A Director | Adamas Pharmaceuticals Inc (ADMS) | 02-Jun-21 | Grant | 5,000 | -- | -- | 3% 197.0K to 202.0K | |
| 23-Mar-21 6:02 PM View: | Prentiss Christopher B Chief Financial Officer | Adamas Pharmaceuticals Inc (ADMS) | 22-Mar-21 | Market Sale | 2,422 | $5.48 | $13,272.60 | (2%) 147.44K to 145.02K | (49%) |
| 23-Mar-21 6:06 PM View: | Shreedhar Vijay Chief Commercial Officer | Adamas Pharmaceuticals Inc (ADMS) | 22-Mar-21 | Market Sale | 1,051 | $5.50 | $5,780.50 | (< 1%) 170.49K to 169.44K | (49%) |
| 16-Mar-21 5:23 PM View: | Mahoney David L Director | Adamas Pharmaceuticals Inc (ADMS) | 12-Mar-21 | Option Exercise | 48,000 | $0.67 | $31,920.00 | 74% 64.78K to 112.78K | |
| 16-Mar-21 5:20 PM View: | MacPhee John A Director | Adamas Pharmaceuticals Inc (ADMS) | 12-Mar-21 | Option Exercise | 192,000 | $0.67 | $127,680.00 | 3840% 5.0K to 197.0K | |
| 15-Mar-21 3:24 PM View: | Papapetropoulos Spyridon Director | Adamas Pharmaceuticals Inc (ADMS) | 11-Mar-21 | Market Purchase | 5,975 | $5.06 | $30,233.50 | 60% 10.0K to 15.97K | 61% |
| 03-Mar-21 5:01 PM View: | McFarlane Neil F. Chief Executive Officer | Adamas Pharmaceuticals Inc (ADMS) | 02-Mar-21 | Grant | 300,000 | -- | -- | 133% 225.0K to 525.0K | |
| 03-Mar-21 4:56 PM View: | Prentiss Christopher B Chief Financial Officer | Adamas Pharmaceuticals Inc (ADMS) | 02-Mar-21 | Grant | 75,000 | -- | -- | 104% 72.44K to 147.44K | |
| 03-Mar-21 4:59 PM View: | Shreedhar Vijay Chief Commercial Officer | Adamas Pharmaceuticals Inc (ADMS) | 02-Mar-21 | Grant | 75,000 | -- | -- | 79% 95.49K to 170.49K | |
| 01-Feb-21 9:37 PM View: | Shreedhar Vijay Chief Commercial Officer | Adamas Pharmaceuticals Inc (ADMS) | 01-Feb-21 | Market Sale | 4,514 | $6.39 | $28,844.50 | (5%) 100.0K to 95.49K | (28%) |
| 01-Feb-21 9:39 PM View: | Prentiss Christopher B Chief Financial Officer | Adamas Pharmaceuticals Inc (ADMS) | 01-Feb-21 | Market Sale | 3,821 | $6.36 | $24,301.60 | (5%) 76.26K to 72.44K | (28%) |
| 22-Jan-21 5:29 PM View: | Prentiss Christopher B Chief Financial Officer | Adamas Pharmaceuticals Inc (ADMS) | 20-Jan-21 | Market Sale | 2,630 | $4.41 | $11,598.30 | (3%) 78.89K to 76.26K | (85%) |
| 24-Nov-20 5:57 PM View: | Papapetropoulos Spyridon Director | Adamas Pharmaceuticals Inc (ADMS) | 22-Nov-20 | Grant | 10,000 | -- | -- | 100% 0 to 10.0K | |
| 02-Nov-20 4:44 PM View: | Prentiss Christopher B Chief Financial Officer | Adamas Pharmaceuticals Inc (ADMS) | 02-Nov-20 | Market Sale | 2,050 | $3.21 | $6,580.50 | (3%) 80.94K to 78.89K | (154%) |
| 01-Sep-20 4:44 PM View: | Richo Anna Director | Adamas Pharmaceuticals Inc (ADMS) | 29-Aug-20 | Grant | 10,000 | -- | -- | 100% 10.0K to 20.0K | |
| 05-Jun-20 6:45 PM View: | Lieberburg Ivan M Director | Adamas Pharmaceuticals Inc (ADMS) | 03-Jun-20 | Grant | 5,000 | -- | -- | 8% 64.0K to 69.0K | |
| 05-Jun-20 6:07 PM View: | Demski Martha J Director | Adamas Pharmaceuticals Inc (ADMS) | 03-Jun-20 | Grant | 5,000 | -- | -- | 38% 13.0K to 18.0K | |
| 05-Jun-20 6:06 PM View: | Bigham Michael Director | Adamas Pharmaceuticals Inc (ADMS) | 03-Jun-20 | Grant | 5,000 | -- | -- | 100% 0 to 5.0K | |
| 05-Jun-20 6:14 PM View: | Mahoney David L Director | Adamas Pharmaceuticals Inc (ADMS) | 03-Jun-20 | Grant | 5,000 | -- | -- | 8% 59.78K to 64.78K | |
| 05-Jun-20 6:12 PM View: | MacPhee John A Director | Adamas Pharmaceuticals Inc (ADMS) | 03-Jun-20 | Grant | 5,000 | -- | -- | 100% 0 to 5.0K | |
| 05-Jun-20 7:42 PM View: | Ericson William W. Director 10% Owner | Adamas Pharmaceuticals Inc (ADMS) | 03-Jun-20 | Grant | 5,000 | -- | -- | < 1% 4.62M to 4.62M | |
| 05-Jun-20 6:09 PM View: | Dier Mardi Director | Adamas Pharmaceuticals Inc (ADMS) | 03-Jun-20 | Grant | 5,000 | -- | -- | 100% 0 to 5.0K | |
| 20-Mar-20 6:07 PM View: | McFarlane Neil F. Chief Executive Officer | Adamas Pharmaceuticals Inc (ADMS) | 18-Mar-20 | Grant | 100,000 | -- | -- | 80% 125.0K to 225.0K | |
| 19-Mar-20 4:21 PM View: | Prentiss Christopher B Chief Financial Officer | Adamas Pharmaceuticals Inc (ADMS) | 17-Mar-20 | Grant | 10,000 | -- | -- | 14% 70.94K to 80.94K | |
| 19-Mar-20 4:24 PM View: | Shreedhar Vijay Chief Commercial Officer | Adamas Pharmaceuticals Inc (ADMS) | 17-Mar-20 | Grant | 23,750 | -- | -- | 33% 71.25K to 95.0K |
